Answers are grounded in this paper and cite their sources.
The current results demonstrated that MTHFD2 was overexpressed in RCC and associated with poor clinical characteristics, vimentin expression, and cellular features connected to malignant disease, thus, implicating MTHFD2 as a potential target for RCC therapy.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: